Company profile: Neogene Therapeutics
1.1 - Company Overview
Company description
- Provider of T cell therapies targeting cancer neo-antigens, developing technologies to engineer designer T cells with optimized neo-antigen specificities to seek and destroy cancer cells. Offers engineered TCR therapies for solid tumors, including a TP53 R175H-targeting TCR therapy currently in Phase I trials in the US.
Products and services
- Designer T-cell Engineering Platform: Develops T cells with neoantigen specificities optimized to seek and destroy cancer cells, neoantigen-specific
- Engineered TCR Therapies: Produces therapies using genetically modified TCRs to target mutated neoantigens in solid tumors, custom-engineered
- TP53 R175H-targeting TCR Therapy: Delivers a TCR-based product targeting TP53 R175H, undergoing Phase I trials in the US, clinical-stage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neogene Therapeutics
Molecular Templates
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for cancer and other serious diseases, leveraging a proprietary engineered toxin body (ETB) platform with unique mechanisms of action. Pipeline includes MT-6402 (PD-L1), MT-8421 (CTLA-4), and MT-0169 (CD38). Operates a multi-product cGMP manufacturing facility in Austin, TX to supply clinical trial materials for internal and partnered ETB programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Templates company profile →
Theranostics Health
HQ: United States
Website
- Description: Provider of proteomics-based diagnostics and research services for drug development companies, developing diagnostic tests to enable personalized cancer therapies tailored to each patient’s tumor, utilizing Laser Capture Microdissection (LCM) and Reverse-phase Protein MicroArrays (RPMA) assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theranostics Health company profile →
GeminX Pharmaceuticals
HQ: Canada
Website
- Description: Provider of novel, targeted cancer therapeutics, dedicated to the discovery, development and commercialization of treatments based on research on the Bcl-2 cell death regulation pathway, including the discovery of GX15-070 (obatoclax), a novel small molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeminX Pharmaceuticals company profile →
Immago
HQ: United Kingdom
Website
- Description: Provider of antibody-modulating enzyme approaches to enhance antibody-based cancer therapies, applying 'receptor refocusing' to modulate the endogenous antibody repertoire and enhance immune-mediated killing of cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immago company profile →
IsoRay
HQ: United States
Website
- Description: Provider of state-of-the-art, personalized brachytherapy products that offer more cost-effective cancer treatment, utilizing a unique isotope for the treatment of both common and difficult-to-treat cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IsoRay company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neogene Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neogene Therapeutics
2.2 - Growth funds investing in similar companies to Neogene Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neogene Therapeutics
4.2 - Public trading comparable groups for Neogene Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →